Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML.
Saved in:
| Title: | Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AML. |
|---|---|
| Authors: | Fiskus W; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Mill CP; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Piel J; Foghorn Therapeutics Cambridge Massachusetts United States., Collins M; Foghorn Therapeutics Cambridge Massachusetts United States., Hentemann M; Foghorn Therapeutics Cambridge Massachusetts United States., Cuglievan B; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Birdwell CE; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Das K; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Davis JA; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Hou H; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Jain A; Baylor College of Medicine Houston Texas United States., Malovannaya A; Baylor College of Medicine Houston Texas United States., Flores LB; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Kadia TM; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Daver N; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Sasaki K; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Takahashi K; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Hammond D; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Wang J; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Loghavi S; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Su X; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., DiNardo CD; The University of Texas M.D. Anderson Cancer Center Houston Texas United States., Delwel R; Erasmus MC Cancer Institute Rotterdam The Netherlands., Bhalla KN; The University of Texas M.D. Anderson Cancer Center Houston Texas United States. |
| Source: | HemaSphere [Hemasphere] 2026 Jan 15; Vol. 10 (1), pp. e70289. Date of Electronic Publication: 2026 Jan 15 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101740619 Publication Model: eCollection Cited Medium: Internet ISSN: 2572-9241 (Electronic) Linking ISSN: 25729241 NLM ISO Abbreviation: Hemasphere Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2572-9241 |
|---|---|
| DOI: | 10.1002/hem3.70289 |
